Stockscreener 앱 받기
9.48
2.27%
-0.22
시간 외 거래:
9.37
-0.11
-1.16%
전일 마감가:
$9.70
열려 있는:
$9.74
하루 거래량:
209.46K
Relative Volume:
0.48
시가총액:
$166.40M
수익:
$1.54M
순이익/손실:
$-38.70M
주가수익비율:
-2.03
EPS:
-4.67
순현금흐름:
$-36.86M
1주 성능:
-8.58%
1개월 성능:
-14.36%
6개월 성능:
+7.36%
1년 성능:
-37.14%
1일 변동 폭
$9.44
$9.90
1주일 범위
$9.44
$11.64
52주 변동 폭
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
CRBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.48 | 170.26M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Discipline and Rules-Based Execution in CRBP Response - news.stocktradersdaily.com
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal? - MSN
Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
Corbus declines following early-stage results on oral obesity asset CRB-913 (CRBP:NASDAQ) - Seeking Alpha
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits
CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Int - GuruFocus
CRBP: CRB-913 induced rapid, significant weight loss with minimal side effects in early obesity trials - TradingView — Track All Markets
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - marketscreener.com
Corbus reports positive phase 1 results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913 - TipRanks
Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss - TradingView — Track All Markets
Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CR - GuruFocus
Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913 - TradingView — Track All Markets
Corbus Pharmaceuticals stock rises after promising obesity drug safety data By Investing.com - Investing.com UK
Corbus Pharmaceuticals stock rises after promising obesity drug safety data - Investing.com
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewswire
Corbus to release phase 1a study results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - The Manila Times
Corbus Pharmaceuticals to Announce Phase 1a Results for CRB-913 on December 11, 2025 - Quiver Quantitative
Corbus Pharmaceuticals (NASDAQ: CRBP) to release Phase 1a CRB-913 obesity data on Dec. 11 - Stock Titan
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains - 富途牛牛
Will Corbus Pharmaceuticals Holdings Inc. stock remain a Wall Street favoriteMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock trades below fair valueInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock attracts wealthy investorsEntry Point & Advanced Technical Signal Analysis - Newser
What risks investors should watch in Corbus Pharmaceuticals Holdings Inc. stock2025 AllTime Highs & Intraday High Probability Alerts - Newser
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top dividend aristocrat candidate2025 Big Picture & Real-Time Volume Surge Alerts - Newser
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock bottoming after sell offStop Loss & Free Weekly Watchlist of Top Performers - Newser
Corbus Pharmaceuticals (CRBP) Stock Analysis Report | Financials & Insights - Benzinga
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Behavioral Patterns of CRBP and Institutional Flows - news.stocktradersdaily.com
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock could be top winnerForecast Cut & AI Driven Stock Movement Reports - Newser
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
What analysts say about Corbus Pharmaceuticals Holdings Inc 3371 stockSector Performance Drivers & Free Trading Psychology Sessions - earlytimes.in
What is B. Riley’s Forecast for CRBP FY2029 Earnings? - Defense World
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
(CRBP) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
How interest rate cuts could boost Corbus Pharmaceuticals Holdings Inc. stockPortfolio Performance Summary & Free Long-Term Investment Growth Plans - newser.com
Cannabis Pharmaceuticals Market | Global Market Analysis Report2035 - Fact.MR
Can Corbus Pharmaceuticals Holdings Inc. (3371) stock sustain margin levelsWeekly Gains Summary & High Return Trade Opportunity Guides - newser.com
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top hedge fund pickEarnings Beat & AI Enhanced Trading Signals - newser.com
Can Corbus Pharmaceuticals Holdings Inc. stock surprise with earnings upside2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
What analyst consensus says on Corbus Pharmaceuticals Holdings Inc. stock2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
How hedge fund analytics apply to Corbus Pharmaceuticals Holdings Inc. stockForecast Cut & Daily Risk Controlled Trade Plans - newser.com
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corbus Pharmaceuticals Holdings Inc 주식 (CRBP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cohen Yuval | Chief Executive Officer |
Oct 27 '25 |
Option Exercise |
4.26 |
8,973 |
38,225 |
147,160 |
| Cohen Yuval | Chief Executive Officer |
Oct 24 '25 |
Sale |
17.01 |
18,660 |
317,407 |
138,187 |
| Cohen Yuval | Chief Executive Officer |
Oct 27 '25 |
Sale |
17.14 |
8,973 |
153,797 |
138,187 |
| Moran Sean F. | Chief Financial Officer |
Oct 24 '25 |
Option Exercise |
4.26 |
12,981 |
55,299 |
86,294 |
| Moran Sean F. | Chief Financial Officer |
Oct 24 '25 |
Sale |
17.02 |
12,981 |
220,937 |
73,313 |
0.36%
1.05%
자본화:
|
볼륨(24시간):